MedTrace Logo

Freedom Study: Myfortic in Kidney Transplant Patients

NCT00101738 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 342

Last updated 2011-01-31

No results posted yet for this study

Summary

The primary objective of the study is to evaluate that 3 immunosuppressant regimens will have comparable kidney function results in kidney transplant patients.

Conditions

  • Kidney Transplantation

Interventions

DRUG

Myfortic

Sponsors & Collaborators

Principal Investigators

  • Novartis · Novartis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2005-05-31
Completion
2005-05-31

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Canada
  • Germany
  • Italy
  • Malaysia
  • New Zealand
  • Singapore
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00101738 on ClinicalTrials.gov